These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 12661516)

  • 1. [Molecular mechanisms behind the immunological reaction against gluten in patients with celiac disease].
    Nielsen C; Husby S; Lillevang ST
    Ugeskr Laeger; 2003 Feb; 165(9):917-20. PubMed ID: 12661516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the binding of gluten T-cell epitopes to various human leukocyte antigen class II molecules.
    Bergseng E; Sidney J; Sette A; Sollid LM
    Hum Immunol; 2008 Feb; 69(2):94-100. PubMed ID: 18361933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell response to gluten in patients with HLA-DQ2.2 reveals requirement of peptide-MHC stability in celiac disease.
    Bodd M; Kim CY; Lundin KE; Sollid LM
    Gastroenterology; 2012 Mar; 142(3):552-61. PubMed ID: 22108197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis of celiac disease.
    Koning F
    J Mol Recognit; 2003; 16(5):333-6. PubMed ID: 14523946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses.
    Vader W; Stepniak D; Kooy Y; Mearin L; Thompson A; van Rood JJ; Spaenij L; Koning F
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12390-5. PubMed ID: 14530392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule.
    Kapoerchan VV; Wiesner M; Hillaert U; Drijfhout JW; Overhand M; Alard P; van der Marel GA; Overkleeft HS; Koning F
    Mol Immunol; 2010 Feb; 47(5):1091-7. PubMed ID: 19962195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coeliac disease: dissecting a complex inflammatory disorder.
    Sollid LM
    Nat Rev Immunol; 2002 Sep; 2(9):647-55. PubMed ID: 12209133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disease mechanisms in coeliac disease].
    Sollid LM; Lundin KE
    Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3230-3. PubMed ID: 14714017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celiac disease: caught between a rock and a hard place.
    Koning F
    Gastroenterology; 2005 Oct; 129(4):1294-301. PubMed ID: 16230082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic variance in childhood coeliac disease and the HLA-DQ/DR dose effect.
    Vermeulen BA; Hogen Esch CE; Yuksel Z; Koning F; Verduijn W; Doxiadis II; Schreuder GM; Mearin ML
    Scand J Gastroenterol; 2009; 44(1):40-5. PubMed ID: 18932050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease.
    Dørum S; Qiao SW; Sollid LM; Fleckenstein B
    J Proteome Res; 2009 Apr; 8(4):1748-55. PubMed ID: 19239248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study.
    Kaukinen K; Peräaho M; Collin P; Partanen J; Woolley N; Kaartinen T; Nuutinen T; Halttunen T; Mäki M; Korponay-Szabo I
    Scand J Gastroenterol; 2005 May; 40(5):564-72. PubMed ID: 16036509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celiac disease: how complicated can it get?
    Tjon JM; van Bergen J; Koning F
    Immunogenetics; 2010 Oct; 62(10):641-51. PubMed ID: 20661732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
    Lindfors K; Mäki M; Kaukinen K
    Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that HLA-DQ9 confers risk to celiac disease by presence of DQ9-restricted gluten-specific T cells.
    Bodd M; Tollefsen S; Bergseng E; Lundin KE; Sollid LM
    Hum Immunol; 2012 Apr; 73(4):376-81. PubMed ID: 22342873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celiac disease: from pathogenesis to novel therapies.
    Schuppan D; Junker Y; Barisani D
    Gastroenterology; 2009 Dec; 137(6):1912-33. PubMed ID: 19766641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling of HLA-DQ2 and its interaction with gluten peptides to explain molecular recognition in celiac disease.
    Costantini S; Rossi M; Colonna G; Facchiano AM
    J Mol Graph Model; 2005 Apr; 23(5):419-31. PubMed ID: 15781184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management.
    Schuppan D; Dennis MD; Kelly CP
    Nutr Clin Care; 2005; 8(2):54-69. PubMed ID: 16013224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells.
    de Kauwe AL; Chen Z; Anderson RP; Keech CL; Price JD; Wijburg O; Jackson DC; Ladhams J; Allison J; McCluskey J
    J Immunol; 2009 Jun; 182(12):7440-50. PubMed ID: 19494267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone.
    Kapitány A; Tóth L; Tumpek J; Csípo I; Sipos E; Woolley N; Partanen J; Szegedi G; Oláh E; Sipka S; Korponay-Szabó IR
    Aliment Pharmacol Ther; 2006 Nov; 24(9):1395-402. PubMed ID: 17059521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.